



| | | | |
|-------------------|---|-----|-----------|
| Suggested Formula | Bupivacaine Hydrochloride 0.5% Intravenous Injection (Solution, 100 mL) | FIN | F 005 007 |
|-------------------|---|-----|-----------|

SUGGESTED FORMULATION

| Ingredient Listing | Qty. | Unit | NDC # | Supplier | Lot Number | Expiry Date |
|----------------------------------|---------------|------|-------|----------|------------|-------------|
| Bupivacaine Hydrochloride, USP | 0.500 | g | | | | |
| Benzyl Alcohol, NF | 1.0 | mL | | | | |
| Sodium Chloride, USP | 0.645 | g | | | | |
| Sterile Water For Injection, USP | 80.0 | mL | | | | |
| Sterile Water For Injection, USP | q.s. to 100.0 | mL | | | | |
| Sodium Hydroxide 10% Solution | As required | | | | | |
| Hydrochloric Acid 10% Solution | As required | | | | | |

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light Sensitive (protect from light whenever possible): Benzyl Alcohol

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing error, pH testing, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797*. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



| | | | |
|-------------------|---|-----|-----------|
| Suggested Formula | Bupivacaine Hydrochloride 0.5% Intravenous Injection (Solution, 100 mL) | FIN | F 005 007 |
|-------------------|---|-----|-----------|

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

| Ingredient Listing | Qty. | Unit | Multiplication factor (*): ____ | Processing Error | Qty. to measure |
|------------------------------------|---------------|------|---------------------------------|------------------|-----------------|
| Bupivacaine Hydrochloride, USP § | 0.500 | g | | | |
| Benzyl Alcohol, NF § | 1.0 | mL | | | |
| Sodium Chloride, USP § | 0.645 | g | | | |
| Sterile Water For Injection, USP § | 80.0 | mL | | | |
| Sterile Water For Injection, USP § | q.s. to 100.0 | mL | | | |
| Sodium Hydroxide 10% Solution § | As required | | | | |
| Hydrochloric Acid 10% Solution § | As required | | | | |

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction

IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique

- Equipment sterilization:**
Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.
- Powder-liquid preparations:**
 - In the given order, sequentially add the following ingredients to the Sterile Water for Injection (80.0 mL *plus* processing error adjustments):
 - Bupivacaine Hydrochloride
 - Benzyl Alcohol
 - Sodium Chloride

Specifications: Continuously mix until all solid particles have completely dissolved.

End result: Homogeneous liquid-like solution.

Note: Add the next ingredient, once the previous one has been completely added and dissolved.



| Suggested Formula | Bupivacaine Hydrochloride 0.5% Intravenous Injection (Solution, 100 mL) | FIN | F 005 007 |
|-------------------|---|-----|-----------|
| 3. | <p><u>pH testing:</u></p> <p>A. Draw an appropriate amount of the mixture (Step 2A).</p> <p>B. Test the pH of the sample. It should lie between 4.0 and 6.5.</p> <p>C. <u>If the pH < 4.0, carefully add, in a dropwise fashion, the Sodium Hydroxide 10% Solution to the mixture:</u></p> <ol style="list-style-type: none">1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% Solution to the mixture.2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% Solution.3. Re-test the pH.4. Continue to add the Sodium Hydroxide 10% Solution until the pH of 4.0 to 6.5 is obtained. <p>IMPORTANT: Do not allow the pH to rise above 6.5.</p> <p>D. <u>If the pH > 6.5, carefully add, in a dropwise fashion, the Hydrochloric Acid 10% Solution to the mixture:</u></p> <ol style="list-style-type: none">1. Draw and transfer 1 or 2 drops of the Hydrochloric Acid 10% Solution to the mixture.2. Stir for at least 5 minutes to evenly disperse the Hydrochloric Acid 10% Solution.3. Re-test the pH.4. Continue to add the Hydrochloric Acid 10% Solution until the pH of 4.0 to 6.5 is obtained. <p>IMPORTANT: Do not allow the pH to fall below 4.0.</p> | | |
| 4. | <p><u>Filling to volume:</u></p> <p>A. Add additional Sterile Water For Injection to the above mixture to fill to the required batch size (100.0 mL <i>plus</i> processing error adjustments).</p> <p><u>Specifications:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p> | | |
| 5. | <p><u>Filtering and transferring:</u></p> <p>Aseptically filter the solution through a 0.22-μm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.</p> | | |
| 6. | <p><u>Filter integrity test:</u></p> <p>Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.</p> | | |
| 7. | <p><u>Sterility testing:</u></p> <p>Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.</p> | | |



| | | | |
|-------------------|---|-----|-----------|
| Suggested Formula | Bupivacaine Hydrochloride 0.5% Intravenous Injection (Solution, 100 mL) | FIN | F 005 007 |
|-------------------|---|-----|-----------|

SUGGESTED PRESENTATION

| | | | |
|----------------------------------|--|-------------------------------|--|
| Estimated Beyond-Use Date | 14 days, refrigerated as per USP 797. BUD based on a successful sterility and endotoxin test result. | Packaging Requirements | Sterile, tightly closed, light-resistant injection vials. |
| Auxiliary Labels | 1 Use as directed. Do not exceed prescribed dose. | 7 | Discard container after use. |
| | 2 Keep out of reach of children. | 8 | Keep refrigerated. Do not freeze. |
| | 3 Discard in the presence of particulate matter. | 9 | Do not use if product changes color. |
| | 4 Protect from light. | 10 | Equilibrate to room temperature before use. |
| | 5 Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use. | 11 | May impair mental and/or physical ability. Use care when operating a car or machinery. |
| | 6 Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants. | | |
| Pharmacist Instructions | Add any auxiliary labels specific to the API to the dispensing container as deemed necessary. | | |
| Patient Instructions | Contact your pharmacist in the event of adverse reactions. | | |



| | | | |
|-------------------|---|-----|-----------|
| Suggested Formula | Bupivacaine Hydrochloride 0.5% Intravenous Injection (Solution, 100 mL) | FIN | F 005 007 |
|-------------------|---|-----|-----------|

REFERENCES

| | |
|-----|---|
| 1. | Parenteral Preparations. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 313. |
| 2. | Sensorcaine. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2012</i> : 2422. |
| 3. | Benzyl Alcohol. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 6th Edition</i> . American Pharmaceutical Association; 2009: 64. |
| 4. | Sodium Chloride. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 6th Edition</i> . American Pharmaceutical Association; 2009: 637. |
| 5. | Bupivacaine Hydrochloride. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 1854. |
| 6. | Bupivacaine (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #1495. |
| 7. | Chapter 8: Buffered and Isotonic Solutions. In: Martin, A. <i>Physical Pharmacy, Fourth Edition</i> . Philadelphia, PA: Lippincott Williams & Wilkins; 1993: 169~189. |
| 8. | Chapter 18: Tonicity, Osmoticity, Osmolality and Osmolarity. In: D.B Troy. <i>Remington: The Science and Practice of Pharmacy, 21st Edition</i> . Baltimore, MD: Lippincott Williams & Wilkins; 2006: 250~265 |
| 9. | Bupivacaine Hydrochloride. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 4th Edition</i> . American Pharmaceutical Association; 2009: 80. |
| 10. | Bupivacaine Hydrochloride (Monograph). <i>United States Pharmacopeia XXXIV / National Formulary 29</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2011: 2087. |
| 11. | Bupivacaine. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 181. |
| 12. | USP <797>. <i>United States Pharmacopeia XXXIV / National Formulary 29</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2011: 336. |

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.